Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465948 | 0.87 | MAPT (0.61) | MAPTTP53CHRM1GAALMNA | |
| SCHEMBL5461976 | 0.84 | MAPT (0.56) | MAPTTP53SMN1; SMN2POLBGAA | |
| SCHEMBL5461967 | 0.84 | MAPT (0.56) | MAPTTP53SMN1; SMN2POLBGAA | |
| SCHEMBL14386978 | 0.81 | MAPT (0.60) | MAPTTP53SMN1; SMN2POLBGAA | |
| SCHEMBL7051565 | 0.81 | KDM4E (0.68) | MAPTTP53POLBGAALMNA | |
| SCHEMBL5418162 | 0.79 | SMN1; SMN2 (0.58) | MAPTTP53SMN1; SMN2POLBGAA | |
| SCHEMBL14516827 | 0.77 | LMNA (0.59) | CHRM1SMN1; SMN2LMNAP2RX3 | |
| SCHEMBL13596328 | 0.77 | KDM4E (0.62) | MAPTTP53POLBLMNA | |
| SCHEMBL5544795 | 0.77 | LMNA (0.73) | TP53CHRM1SMN1; SMN2LMNAP2RX3 | |
| SCHEMBL5544822 | 0.77 | LMNA (0.73) | CHRM1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | MAPT 4635/4885TP53 2044/4885CHRM1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.